MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. CYH
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Community Health Systems (CYH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Community Health Systems
NYSE•Healthcare•Medical Care Facilities
$2.97+0.02(0.01%)Pre-market
Market Cap
$395.64M
P/E
1.6x
P/S
0.0x

Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. The company offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. It also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, and direct-to-consumer virtual health visits. Community Health Systems, Inc. was founded in 1985 and is headquartered in Franklin, Tennessee.

D

How this company scores

WeakMetricSide Score: 41/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Profitability (15/25); weakest: Cash & Earnings Quality (7/25).

Profitability15/25
Growth12/25
Balance Sheet & Red Flags7/25
Cash & Earnings Quality7/25
Strengths
Rising earningsProfit converts from growthImproving margins
Grade capped at D
  • Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1.6x5y range 0.8x – 12.1x
P/E 1.6x · near its 10-quarter median

Currently near its 10-quarter median.

P/S · 0.0x5y range 0.0x – 0.1x
P/S 0.0x · near its 20-quarter median

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.5x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume
Market Cap $395.64M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$11.98B
5Q
Q. Revenue
$2.83B
2Q
TTM EBITDA
$1.80B
36%
TTM Op. Income
$1.36B
2Q
Q. Op. Income
$389.00M
24%
TTM Net Income
$252.00M
2Q
Q. Net Income
$70.00M
75%
EPS
$0.51
76%
Shares Out.
$135.49M
7Q
$11.98B in TTM revenue declined 5.2% YoY, reaching $2.83B last quarter. TTM EBITDA of $1.80B and TTM operating income of $1.36B show growth is flowing through to the bottom line. TTM net income of $252.00M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 5 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
85.8%
1%
EBITDA Margin
17.6%
11%
Op. Margin
13.8%
16%
Net Margin
2.5%
72%
Op. margin of 13.8% is down 2.6% YoY — costs are rising relative to revenue. Net margin at 2.5% and gross margin of 85.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 16% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
1.6x
P/S Ratio
0.0x
8%
P/B Ratio
N/A
At 1.6x P/E, the stock trades below typical market levels. P/S of 0.0x and P/B of 0.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$12.18B
6Q
Cash
$149.00M
67%
Long-Term Debt
$9.55B
7Q
Book Value
$-1.39B
15%
D/E Ratio
N/A
Debt/EBITDA
19.2
9%

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$88.00M
0%
TTM Free Cash Flow
$-185.00M
236%
FCF Margin
-1.5%
244%
FCF / Net Income
-0.7
3Q
TTM FCF of $-185.00M on $88.00M in operating cash flow. The FCF / Net Income ratio of -0.7x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 236% — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Revenue Decline

Watch

Revenue has softened, declining in 5 quarters. Watch for further erosion.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Share Dilution

Watch

Shares outstanding rose 2.4% — mild dilution. Compare to earnings growth to assess the net per-share impact.